EcoDrugPlus

Matrix Metalloproteinase-14-Like

Ensembl ID : ENSCVAG00000006040
Gene Symbol: LOC107087725
3 Cross references
198 Possible Orthologues:

Mechanistic Target Of Rapamycin Kinase

Ensembl ID : ENSCVAG00000001414
Gene Symbol: MTOR
3 Cross references
222 Possible Orthologues:

Melanocortin 1 Receptor

Ensembl ID : ENSCVAG00000020436
Gene Symbol: MC1R
1 Cross references
159 Possible Orthologues:

Melanocortin 4 Receptor

Ensembl ID : ENSCVAG00000004533
Gene Symbol: MC4R
1 Cross references
211 Possible Orthologues:

Melanoma Receptor Tyrosine-Protein Kinase-Like

Ensembl ID : ENSCVAG00000012573
Gene Symbol: LOC107098892
2 Cross references
212 Possible Orthologues:

Melatonin Receptor 1a

Ensembl ID : ENSCVAG00000013074
Gene Symbol: MTNR1A
3 Cross references
190 Possible Orthologues:

Membrane Metalloendopeptidase

Ensembl ID : ENSCVAG00000005658
Gene Symbol: MME
4 Cross references
234 Possible Orthologues:

Metabotropic Glutamate Receptor 2-Like

Ensembl ID : ENSCVAG00000005733
Gene Symbol: LOC107096105
3 Cross references
210 Possible Orthologues:

Metabotropic Glutamate Receptor 3-Like

Ensembl ID : ENSCVAG00000004065
Gene Symbol: LOC107090533
3 Cross references
212 Possible Orthologues:

Metabotropic Glutamate Receptor 5-Like

Ensembl ID : ENSCVAG00000019652
Gene Symbol: LOC107087909
3 Cross references
212 Possible Orthologues:

Methionyl Aminopeptidase 2

Ensembl ID : ENSCVAG00000015520
Gene Symbol: METAP2
4 Cross references
229 Possible Orthologues:

Microtubule-Associated Protein Tau-Like

Ensembl ID : ENSCVAG00000013676
Gene Symbol: LOC107090931
2 Cross references
205 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).